ADMA Biologics Triggers Bearish KDJ Death Cross, Marubozu Candlestick Pattern

ADMA Biologics's 15-minute chart has exhibited a KDJ Death Cross and a Bearish Marubozu on October 8, 2025 at 11:15. This signals a shift in the momentum of the stock price towards a downward trend, with a potential for further decline. The sellers currently dominate the market, and it is likely that the bearish momentum will continue.

Adma Biologics (ADMA) has been experiencing a significant shift in its stock price momentum, as indicated by a KDJ Death Cross and a Bearish Marubozu on October 8, 2025, at 11:15. This technical signal suggests a potential downward trend, with sellers currently dominating the market. Investors should be cautious as the bearish momentum may continue.

Despite the bearish technical indicators, Adma Biologics has shown promise in its earnings forecasts. Analysts predict an earnings per share (EPS) of $0.16 for the upcoming quarter, representing a 6.67% growth compared to the same period last year. Additionally, the consensus estimate projects revenue to be $130.1 million, indicating an 8.56% increase year-over-year. For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, reflecting changes of +16.33% and +18.82%, respectively, from the preceding year Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Valuation metrics also provide insights into the stock's performance. Adma Biologics is currently trading at a Forward P/E ratio of 25.72, which is a premium compared to the industry average Forward P/E of 18.92. The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 80, placing it in the top 33% of all 250+ industries Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Investors should monitor Adma Biologics closely, especially in light of the recent technical signals and the company's positive earnings forecasts. The Zacks Rank system, which incorporates estimate changes, currently rates Adma Biologics as a #3 (Hold), indicating a cautious stance.